Source facts
FDA issued an approval letter for IOPIDINE on 2026-03-20. The source metadata identifies NDA 020258 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
IOPIDINE — FDA Approval Letter (NDA 020258)
Issued to HARROW EYE. Application is approved as submitted.
Issued
March 20, 2026Application
NDA 505b1 • 020258
Product
IOPIDINE
Company
HARROW EYE
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for IOPIDINE?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 020258.
- 3Submission: supplement.
- 4Sponsor: HARROW EYE.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the IOPIDINE approval letter
Is IOPIDINE FDA approved?
This letter documents an FDA approval action: FDA approved NDA 020258 for IOPIDINE, sponsored by HARROW EYE, on March 20, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 020258?
NDA 020258 is the application under which FDA issued this approval letter for IOPIDINE to HARROW EYE. The letter is dated March 20, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.